Chordate Medical is now listed on the Nasdaq First North Growth Market. At the bell ringing ceremony on February 15th, Chairman of the Board Henrik Rammer gave a short speech about the company and its future, whereafter company CEO Anders Weilandt rang the Nasdaq bell.
Chordate’s change of stock exchange list is judged by the company’s board to increase the company’s awareness both in Sweden and internationally, make it easier for industrial investors to become shareholders, and have a positive impact on the company’s relationships with partners and potential customers.